Stanford Study Reveals Genetic Trigger Behind Some Schizophrenia Cases
News Oct 24, 2005
Researchers at the Stanford University School of Medicine, Lucile Packard Children's Hospital and the University of Geneva have announced that a gene that regulates dopamine levels in the brain is involved in the development of schizophrenia in children at high risk for the disorder.
The finding adds to mounting evidence of dopamine's link to psychiatric and neurological disorders. It may also allow physicians to pinpoint a subset of these children for treatment before symptoms start.
“The hope is that we will one day be able to identify the highest-risk groups and intervene early to prevent a lifetime of problems and suffering,” said Allan L. Reiss, MD.
“As we gain a much better understanding of these disorders, we can design treatments that are much more specific and effective.”
Reiss is the Robbins Professor of Psychiatry and Behavioral Sciences at Stanford and director of the school's Center for Interdisciplinary Brain Sciences Research.
The research, which will be published online Oct. 23 will appear in print in the November issue of Nature Neuroscience.
Dopamine levels have been implicated in many neurological conditions, including Parkinson's disease and psychosis.
Data from this and other studies suggest a kind of Goldilocks effect for this important chemical messenger: too little or too much can dramatically interfere with normal cognition, behavior and motor skills.
Reiss and the study's first author Doron Gothelf, MD, a child psychiatrist and postdoctoral scholar at Stanford, studied 24 children with a small deletion in one copy of chromosome 22.
About 30 percent of children with this deletion, which occurs in about one in 4,000 births, will develop schizophrenia or a related psychotic disorder.
These children also often have special facial features, cardiac defects and cleft anomalies that often make their speech hypernasal.
Although these characteristics make it possible to identify them before psychiatric disorders develop, the disorder, called velocardiofacial syndrome, is under-diagnosed and under-recognized in this country despite its link to schizophrenia.
“We have strong evidence that this deletion is a major risk factor for the development of schizophrenia or related psychotic disorders,” said Reiss.
“We asked, 'What is it about this deletion that causes such an increase in risk?”
The answer lay in the fact that one of the missing genes encodes a dopamine-degrading protein called COMT. Natural variations in the gene generate two versions of the protein: one with high activity, one with low.
Because most people have two copies of the gene, it doesn't usually matter which versions of COMT they inherit; high-high, high-low and low-low all seem to provide enough COMT activity to get the job done (though some combinations confer a mild advantage for some cognitive tasks).
But children with the deletion have only the one copy that remains on their intact chromosome 22.
Reiss and Gothelf, who is also an assistant professor at Tel Aviv University in Israel, surmised that a single copy of the low-activity COMT might not dispose of enough dopamine to produce optimal brain function.
They set out to determine if the clinical course of the children with deletions who developed schizophrenia varied with the version of the COMT protein they had.
The researchers matched the age, gender, ethnicity and IQ of the 24 children with the deletion, with 23 children with developmental disabilities of unknown causes.
They then tested their subjects' verbal IQ and cognitive abilities. None of the children in either group had yet experienced any psychotic symptoms.
They also measured the size of the children's prefrontal cortex - an area of the brain where COMT activity is particularly important and that is strongly associated with schizophrenia.
They repeated the same tests after about five years, when their subjects reached late adolescence or early adulthood.
As expected, about 29 percent, or seven, of the children with the deletion had developed a psychotic disorder by the second round of testing, compared with only one child in the control group.
Of these seven, those with the low-activity version of COMT had experienced a significantly greater drop in their verbal IQ and expressive language skills and a markedly greater decrease in the volume of their prefrontal cortex than did their peers with the more highly active version of COMT.
The psychotic symptoms of the low-activity subset were also significantly more severe.
In contrast, members of the control group experienced no significant differences in any of these categories, regardless of their COMT profiles.
“What's interesting about this finding is that the disease course in the individuals with low-activity COMT looked remarkably like idiopathic schizophrenia,” said Reiss, who hopes to use this and future data to develop a model for other causes of schizophrenia.
“Although this deletion probably causes less than 5 percent of schizophrenia cases, it's the only well-defined genetic risk factor we have right now,” said Reiss.
“In the future, researchers will likely discover multiple causes of this disorder, with complex interactions between genetic and environmental risk factors.”
“But COMT activity appears to be an important contributory factor for the development of psychosis in the chromosome 22 deletion syndrome.”
The researchers next plan to extend their studies to younger children, and to repeat the above study using multiple time points to catch the ongoing development of the disorder.
Genes Can Influence the Mutation, Activity of Nearby GenesNews
Study shows that a gene’s neighborhood can influence whether and how the activity of a gene changes.READ MORE
Brain Regions Implicated in Mental Disorders Influenced by Neanderthal GenesNews
Findings indicate that the more a person’s genome carries genetic vestiges of Neanderthals, the more certain parts of his or her brain and skull resemble those of humans’ evolutionary cousins that went extinct 40,000 years ago.READ MORE
Acquisition Sees Agilent Gain Powerful NGS IP PortfolioNews
Agilent Technologies announces its acquisition of the molecular and sample barcoding portfolios of Population Genetics Technologies.READ MORE
Comments | 0 ADD COMMENT
International Conference on Genomics and Pharmacogenomics
Jul 18 - Jul 19, 2018
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018